• Home
  • >
  • Gland Pharma Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/gland-pharma-ltd.png Logo

Gland Pharma Ltd Financial Statement

Gland Pharma Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue1,141.251,051.78919.28
Operating Expense728.37663.57624.71
Net Profit276.81257.53187.58
Net Profit Margin24.2524.4920.41
Earning Per Share16.8115.6411.39
EBIDTA409.29385.26287.04
Effective Tax Rate22.1322.319.99

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Gland Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual3,624.64,400.713,462.88
Operating Expenses Annual2,599.842,890.562,160.65
Operating Profit Annual1,208.771,734.091,437
Interest Annual7.455.243.41
Depreciation145.68109.6798.58
Net Profit Annual781.041,211.66996.96
Tax Annual273.54406.89337.85

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Gland Pharma Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning318.82492.46169.5
Cash Flow from Operations363.97790.77604.93
Cash Flow from Investing1,211.19-999.31-1,520.42
Cash Flow from Financing14.9234.91,238.46
Cash Flow at the End1,908.9318.82492.46

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Gland Pharma Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)33.3539.441.5
PBIT Margin (%)29.336.938.64
PBT Margin (%)25.3629.8627.31
Net PROFIT Margin (%)21.4527.5428.79
Return On Networth / Equity (%)10.3318.5520.88
Return On Networth /Employed(%)14.0424.8427.99
Return On Assets (%)10.318.4520.73
Total Debt / Equity(X)TBATBATBA
Asset Turnover Ratio (%)0.480.670.72

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Gland Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual1,570.551,512.19954.23
Total Current Assets Annual6,900.815,852.085,123.64
Non Current Assets Annual1,876.731,981.541,372.44
Total Shareholders Funds Annual7,958.727,157.625,903.24
Total Assets Annual8,777.547,833.626,496.08

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Gland Pharma Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Gland Pharma Ltd has a market capitalization of 20,893.95 Cr. Value Research classifies it as a Large-Cap company.

Yes, Gland Pharma Ltd is debt-free with a debt-to-equity ratio of 0.00.

In FY 2023, Gland Pharma Ltd recorded a total revenue of approximately 3,624.6 Cr marking a significant milestone in the company's financial performance.

Gland Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and 0.0% annually, respectively..

Gland Pharma Ltd's current PE ratio is 26.75.

Gland Pharma Ltd's ROCE averaged 19.5% from the FY ending March 2021 to 2023, with a median of 22.6%. It peaked at 22.7% in March 2022, reflecting strong capital efficiency over the period..

Gland Pharma Ltd's latest EBIT is Rs. 1,062.03 Cr, surpassing the average EBIT of Rs. 1,341.35 Cr over the 5 years..